10 Great Cheap Stocks to Buy Now for Under $10 in 2018

Share on StockTwits
As the P/E ratios of most S&P 500 companies look very expensive and the market continues to regularly hit new all-time highs, it's very difficult to find cheap stocks to buy now.

This goes for both share price, since most stocks are trading higher on a per-share basis, and valuation relative to earnings. Right now, the typical S&P 500 company is trading at about 25 times forward-looking earnings. Histortically, S&P 500 companies have traded at about 15 times earnings in more normal markets.

While the S&P 500 as a whole is expensive, there are still a handful undervalued stocks that are trading at less than $10.00 per share. Opportunities for value exist if you know where to look. Putting together a list of cheap stocks to buy now requires looking into some smaller, riskier, unloved or undiscovered parts of the market.

Some of these companies are great ideas because they're too small and too risky to attract the interest of most mutual funds and professional money managers. Others have been beat up by the market after a period of slowing earnings and profits, but are now trying to turn around and bounce back.

Each of these 10 stock picks all share a common characteristic, a super-low share price of $10.00 or less.

#1 - Forward Pharma A/S (NASDAQ:FWP)

Current Price: $4.31
P/E Ratio: 1.1
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.00 (294.4% Upside)

Forward Pharma A/S logoForward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company's clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis. The Company's DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF's side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.

#2 - Acacia Research (NASDAQ:ACTG)

Current Price: $3.75
P/E Ratio: 1.6
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $6.50 (73.3% Upside)

Acacia Research logoAcacia Research Corporation, through its subsidiaries, invests in, licenses and enforces patented technologies. The Company's operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. The Company's operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The Company's operating subsidiaries own or control the rights to multiple patent portfolios, which include the United States patents and certain foreign counterparts, covering technologies used in a range of industries.

#3 - Seadrill Partners (NYSE:SDLP)

Current Price: $3.89
P/E Ratio: 1.6
Consensus Rating: Buy
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.00 (105.7% Upside)

Seadrill Partners logoSeadrill Partners LLC is an offshore deepwater drilling company. The Company owns, operates and acquires offshore drilling units. The Company's subsidiaries include Seadrill Operating LP, Seadrill Capricorn Holdings LLC and Seadrill Partners Operating LLC (collectively, OPCO). The Company's segment is OPCO's fleet. The Company provides operations in oil and gas exploration and development in regions across the world and its customers include integrated oil and gas companies, state-owned national oil companies, and independent oil and gas companies. The Company's fleet includes semi-submersibles, including West Aquarius, West Capricorn, West Leo and West Sirius; the semi-tender rig West Vencedor; the tender rigs, T-15 and T-16, and drillships, such as West Auriga, West Vela, West Capella and West Polaris.

#4 - Advanced Emissions Solutions (NASDAQ:ADES)

Current Price: $8.29
P/E Ratio: 1.9
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.67 (125.2% Upside)

Advanced Emissions Solutions logoADA-ES, Inc. (ADA) develops, offers, and implements environmental technologies and provides equipment and specialty chemicals that enable coal-fueled power plants to meet emissions regulations by enhancing existing air pollution control equipment. ADA's wholly owned subsidiaries include Advanced Emissions Solutions, Inc., ADA Intellectual Property, LLC and ADA Environmental Solutions, LLC. ADA holds a 42.5% controlling interest in Clean Coal Solutions, LLC. It operates in three segments: Refined coal (RC), Emission control (EC) and CO2 capture (CC). ADA is a supplier of mercury control equipment and services to the EC markets. It also offers dry sorbent injection systems (DSI) to control SO2 and acid gases. Products, such as the Company's CyCleanTM and M-45TM technologies, its pre-combustion coal treatment processes that provide electric power generators mercury emission control. In September 2012, it acquired the assets of Bulk Conveyor Specialist Inc. and Bulk Conveyor Services, Inc.

#5 - Ophthotech (NASDAQ:OPHT)

Current Price: $3.01
P/E Ratio: 1.9
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.00 (32.9% Upside)

Ophthotech logoOphthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.

#6 - Halcon Resources (NYSE:HK)

Current Price: $8.25
P/E Ratio: 2.1
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.14 (22.9% Upside)

Halcon Resources logoHalcon Resources Corporation is an independent energy company focused on the acquisition, production, exploration and development of onshore liquids-rich oil and natural gas assets in the United States. The Company's estimated total proved oil and natural gas reserves are approximately 146.8 million barrels of oil equivalent (MMBoe), consisting of over 120.7 million barrels of oil (MMBbls), approximately 13.0 MMBbls of natural gas liquids and over 78.4 billion cubic feet (Bcf) of natural gas. The Company's oil and natural gas assets consist of undeveloped acreage positions in unconventional liquids-rich basins/fields. The Company has reserves in its core resource plays of approximately 143.6 MMBoe, of which over 92% are oil and natural gas liquids, and approximately 55% are proved developed. The Company has working interests in approximately 123,000 net acres prospective in the Bakken/Three Forks formations in North Dakota.

#7 - AU Optronics (NYSE:AUO)

Current Price: $4.57
P/E Ratio: 3.6
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 3 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: N/A

AU Optronics logoAU Optronics Corp. is a thin-film-transistor liquid-crystal display (TFT-LCD) panel provider. The Company operates in two business segments: display business and solar business. Through Display business segment, the Company designs, develops, manufactures, assembles and markets flat panel displays and most of its products are TFT-LCD panels. Its panels are primarily used in televisions, monitors, mobile personal computers (PCs), mobile devices and commercial and other applications (such as displays for automobiles, industrial PCs, automated teller machines, point of sale terminals and pachinko machines). Through Solar business segment, the Company is capable of manufacturing upstream and midstream products, such as ingots, solar wafers and solar cells. Through the Company's subsidiaries AUO Crystal Corp. and M.Setek Co., Ltd. (M.Setek), it mainly focuses on research, production and sales of solar materials, such as ingots and solar wafers.

#8 - Entravision Communication (NYSE:EVC)

Current Price: $7.30
P/E Ratio: 3.9
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.00 (-4.1% Upside)

Entravision Communication logoEntravision Communications Corporation is a media company. The Company reaches and engages Hispanics in the United States and certain border markets of Mexico across media channels and advertising platforms. The Company operates through three segments: television broadcasting, radio broadcasting and digital media. As of December 31, 2016, the Company owned and operated 54 television stations located primarily in California, Colorado, Connecticut, Florida, Kansas, Massachusetts, Nevada, New Mexico, Texas and Washington, District of Columbia. It owns and operates Spanish-language radio stations in the United States. As of December 31, 2016, its radio stations consisted of 38 frequency modulation (FM) and 11 amplitude modulation (AM) stations located in Arizona, California, Colorado, Florida, Nevada, New Mexico and Texas. The digital media segment provides digital advertising solutions that allow advertisers to reach online Hispanic audiences throughout the United States and Mexico.

#9 - Sorl Auto Parts (NASDAQ:SORL)

Current Price: $6.82
P/E Ratio: 4.4
Consensus Rating: Buy
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.00 (46.6% Upside)

Sorl Auto Parts logoSORL Auto Parts, Inc., through its interests in the Ruili Group Ruian Auto Parts Co., Ltd., a Sino-foreign joint venture (Joint Venture), develops, manufactures and distributes automotive brake systems and other safety related auto parts to automotive original equipment manufacturers (OEMs), and the related aftermarket both in China and abroad. The Company operates through two segments: Commercial Vehicle Brake Systems and Passenger Vehicle Brake Systems. The Company's products are principally used in different types of commercial vehicles, such as trucks and buses, and include a range of products covering approximately 65 categories and over 2,000 specifications in automotive brake systems. The Company sells its products to approximately 70 vehicle manufacturers, including all of the primary truck manufacturers in China.

#10 - Genworth Financial (NYSE:GNW)

Current Price: $3.17
P/E Ratio: 4.5
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.88 (22.2% Upside)

Genworth Financial logoGenworth Financial, Inc. (Genworth) is a financial security company. The Company provides insurance, wealth management, investment and financial solutions. As of December 31, 2011, the Company had more than 15 million customers, with a presence in more than 25 countries. The Company operates in Insurance, Mortgage Insurance and Corporate and Runoff. The Mortgage Insurance Division includes the business segments, such as International Mortgage Insurance and U.S. Mortgage Insurance. The Corporate and Runoff Division includes the Runoff segment and Corporate and Other activities. In September 2013, Genworth Financial, Inc closed the sale of its Wealth Management business, including Genworth Financial Wealth Management and alternative solutions provider, the Altegris companies, to a partnership of Aquiline Capital Partners and Genstar Capital.







More on MarketBeat
15 Healthcare Stocks that Analysts Love15 Healthcare Stocks that Analysts Love
8 Retail Stocks to Own For the Long Haul8 Retail Stocks to Own For the Long Haul
Analysts Hate These 12 StocksAnalysts Hate These 12 Stocks
12 Marijuana Stocks to Buy Now12 Marijuana Stocks to Buy Now
15 Energy Stocks Analysts Love the Most15 Energy Stocks Analysts Love the Most
Top Fifteen Highest-Rated Dividend CompaniesTop Fifteen Highest-Rated Dividend Companies
20 Stocks Analysts Can20 Stocks Analysts Can't Stop Upgrading


Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.